Nutrition 21: Adding chromium histidinate to diet improves mood, lessens carb cravings
PURCHASE, N.Y. Nutrition 21 on Thursday reported that the addition of chromium histidinate to one’s diet significantly increased brain serotonin levels, citing recently presented results of a research study before the Experimental Biology 2009 conference in New Orleans that tested its chromium histidinate in animal models of obesity and of diabetes.
Increased serotonin levels are known to improve mood and decrease carbohydrate cravings.
Additional research on chromium was presented by scientists from the U.S.D.A. and from the Medical College of Georgia. The U.S.D.A. study in animals found that chromium histidinate and chromium picolinate reduced the expression of the gene in the brain that produces TAU proteins. The TAU protein is involved in the development of Alzheimer’s disease. Research by MCG demonstrated that high doses of chromium picolinate are safe and does not cause kidney dysfunction in animal models of obesity and of diabetes.
“These results provide a mechanism by which chromium histidinate and chromium picolinate improves mood and reduces carbohydrate cravings,” stated James Komorowski, Nutrition 21 VP technical services and scientific affairs. “The research by the U.S.D.A. provides evidence to support additional research in new chromium applications that address significant quality of life issues in our society. The research by MCG continues to support the safety of chromium picolinate, even at high doses.”
Nutrition 21 owns issued and pending patents on multiple uses of chromium, chromium picolinate and chromium histidinate, the company stated.
“We believe that the research work done by independent organizations like the U.S.D.A. and Medical College of Georgia continues to demonstrate the safety and efficacy of our chromium products in conditions such as obesity and diabetes, and begins to demonstrate the potential to address additional health issues like Alzheimer’s Disease,” commented Michael Zeher, president and CEO of Nutrition 21.
CDC recommends H1N1 antiviral for pregnant women
ATLANTA During its daily briefing with journalists Tuesday, the Centers for Disease Control and Prevention noted that doctors ought to prescribe antiviral medicines to pregnant women suspected of being infected with the novel H1N1 influenza virus sooner rather than later.
“As many of you know, pregnant women are at higher risk of complications of influenza, whether it’s the seasonal influenza or pandemics of the past,” commented Anne Schuchat, interim deputy director for science and public health at CDC. “We have about 20 cases under investigation right now where the H1N1 virus has been found in association with pregnancy. We’re continuing to understand the illness in these patients, and a few of the patients have had severe complications. We think it’s very important when doctors are caring for pregnant women who they suspect may have influenza, that they issue prompt treatment with antiviral medicines.”
Schuchat acknowledged that both doctors and patients are hesitant to take medicines like antivirals for fear of harming the unborn baby.
“[However], the experts who have looked into this situation really strongly say that the benefits of using antiviral drugs to treat influenza in a pregnant woman outweigh the theoretical concerns about the drugs,” Schuchat said. “So, while we don’t have lots and lots of experience yet with this H1N1 virus in pregnancy … we really want to get the word out about the likely benefits of prompt antiviral treatment in pregnancy when you’re suspecting influenza.”
Schuchat noted that the CDC will be issuing clinical data around the pregnancy cases currently under investigation in an upcoming issue of the Morbidity and Mortality Weekly Report.
As of Wednesday at 11 a.m., the CDC has identified 3,352 cases of novel H1N1 influenza across 45 states and the District of Columbia. The death toll remains at three.
PAD patients that use aspirin reduce risk of stroke, study finds
CHICAGO In patients with peripheral artery disease, a blocked leg blood vessel, prophylactic use of aspirin either alone or in conjunction with dipyridamole did not reduce incidence of heart disease, but did reduce the risk of a nonfatal stroke, research published May 13 in the Journal of the American Medical Association has found.
The finding comes from a meta-analysis of studies around aspirin use with PAD.
Overall, studies found a 12% reduction in all cardiovascular events among patients receiving aspirin therapy, compared with those who were not. And while that reduction was considered statistically insignificant, the incidence of nonfatal stroke was 34% lower in the aspirin-taking group.